The Federal Trade Commission has brought an administrative complaint against three of the country's largest pharmacy benefit managers (PBMs), accusing them of engaging in practices that artificially inflated the list price of insulin drugs.

The Federal Trade Commission brought action against the three largest prescription drug benefit managers (PBMs)—Caremark Rx (a CVS company), Express Scripts (ESI), and OptumRx—and their affiliated group purchasing organizations (GPOs) for engaging in anticompetitive and unfair rebating practices that have artificially inflated the list price

The US Federal Trade Commission sued units of CVS Health Corp., Cigna Group and UnitedHealth Group Inc. on Friday, accusing the drug middlemen of engaging in illegal rebate programs that drove up the price of insulin.

The U.S. Federal Trade Commission sued the country's three largest pharmacy benefit managers on Friday, accusing them of steering diabetes patients towards higher priced insulin in order to reap millions of dollars in rebates from pharmaceutical companies.

Pharmacy-benefit managers owned by CVS, Cigna and UnitedHealth “artificially inflated” prices for lifesaving medications, regulator alleges.

The Federal Trade Commission on Friday filed lawsuits against three prescription drug benefit managers or PBMs over concerns the companies are artificially inflating the list price of insulin drugs.

The Federal Trade Commission took action Friday against the three largest pharmacy benefit managers, accusing the companies of “engaging in anticompetitive and unfair rebating practices that have artificially inflated the list price of insulin drugs,

The Federal Trade Commission on Friday filed a lawsuit over insulin prices against the three largest pharmaceutical middlemen that negotiate prescription drug prices, arguing that the companies artificially inflate the costs of the lifesaving diabetes drug for patients.